NasdaqGS:TEMLife Sciences
A Look At Tempus AI (TEM) Valuation After New Cancer Registry Collaboration And Genomic Profiling Study
Tempus AI (TEM) is back on investors’ radar after two cancer focused updates, a new collaboration on a pediatric acute myeloid leukemia registry, and fresh evidence supporting its genomic profiling capabilities.
See our latest analysis for Tempus AI.
Despite the positive sentiment around its pediatric leukemia registry and genomic profiling study, Tempus AI’s recent 30 day share price return of 15.81% and year to date share price return of 21.20% point to fading momentum, while the 1 year...